- The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. Piccini, P., Brooks, D.J., Korpela, K., Pavese, N., Karlsson, M., Gordin, A. J. Neurol. Neurosurg. Psychiatr. (2000)